## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims

1. (currently amended) A method for treating lung cancer or pancreatic cancer, which comprises administering to a mammal in need of such treatment an <u>effective</u> amount of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), or a pharmaceutically acceptable salt thereof, in a range of 500 4900 mg/m<sup>2</sup> and administering an effective amount of gemcitabine, wherein the DMXAA, or the pharmaceutically acceptable salt thereof, and the gemcitabine are administered in a ratio in the range of 1:15 to 1:10 (DMXAA:gemcitabine).

## 2. (canceled)

- 3. (**previously presented**) The method according to claim 1 wherein the DMXAA or pharmaceutically acceptable salt thereof and gemcitabine are administered concomitantly.
- 4. (**currently amended**) A method for treating lung cancer or pancreatic cancer, which comprises administering to a mammal in need of such treatment an <u>effective</u> amount of DMXAA, or pharmaceutically acceptable salt thereof, in a range of 500–4900 mg/m<sup>2</sup> and <u>administering</u> an effective amount of gemcitabine, wherein the DMXAA or pharmaceutically acceptable salt thereof and the gemcitabine are administered sequentially in a ratio in the range of 1:15 to 1:10.

## **5-28.** (canceled)